June Lee

Lee served as the medical director of the High-Risk Asthma Clinic at San Francisco General Hospital.^[5] She maintained an independent research program prior to Genentech, funded by the American Lung Association, to investigate IL-13 induced transcription,^[6] among other pulmonary treatments.

Lee joined the clinical development organization at Genentech initially to help launch a new biologic treatment for asthma (the data from a large respiratory study – TENOR – that resulted in multiple insights into risk factors and demographics for asthma sufferers).^[7]

Lee holds a professorship at UCSF in the School of Medicine.^[8] She was the director of Early Translational Research at UCSF.^[9] From 2011 to 2017, Lee served as the director of the Catalyst Program inside UCSF, which served as an internal incubator for entrepreneurial ideas from faculty, in addition to providing de-risking outsourcing partnerships and educational modules for graduate students.^[10]

Lee served as the chief operating officer and chief development officer for MyoKardia.^[1] Myokardia was acquired by Bristol Myers Squibb for $13.1 billion in November 2020.^[11]

June was the President and Founding CEO of Esker Therapeutics.^[12]

She is a member of the board of directors^[13] for Novus Therapeutics,^[14] GenEdit^[15] and serves on the scientific advisory board for Foresite Labs^[16] and Aer Therapeutics. She also serves on the advisory board for the Johns Hopkins University Center for Therapeutic Translation.

Lee has been a volunteer member of the Council of Korean Americans since 2013, and currently sits on its board of directors and previously served as chair of the board.^[17] She has served previously as chair of the Drug, Device, Discovery, and Development Workgroup of UC BRAID (University of California Biomedical Research Acceleration Integration and Development).^[5]

Lee is a fellow of the American College of Chest Physicians.